Factor V, tissue factor pathway inhibitor, and east Texas bleeding disorder

26Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.

Abstract

In a report reading like a fascinating detective story, Vincent and colleagues crack the mysterious case of east Texas bleeding disorder. They show that affected individuals have a mutation in exon 13 of the coagulation F5 gene that causes increased expression of an alternatively spliced transcript, which encodes a previously unrecognized factor V (FV) isoform they call FV-short. This FV isoform lacks a large portion of the B domain of FV, which is normally released upon the proteolytic activation of FV by thrombin and binds tightly to the coagulation regulator tissue factor pathway inhibitor-α (TFPIα). This interaction leads to an approximately 10-fold increase in the level of TFPIα circulating in plasma and a resultant anticoagulant effect that produces a hemorrhagic diathesis.

Cite

CITATION STYLE

APA

Broze, G. J., & Girard, T. J. (2013, September 3). Factor V, tissue factor pathway inhibitor, and east Texas bleeding disorder. Journal of Clinical Investigation. https://doi.org/10.1172/JCI71220

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free